Novoeight Kit
NDC 0169-7850
Product Information
Novoeight (antihemophilic factor recombinant) is a BLA-approved product labeled by Novo Nordisk. This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is supplied as a kit. This product entry covers the primary NDC 0169-7850 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0169-7850?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT (UNII: P89DR4NY54)
- ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT (UNII: P89DR4NY54) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- HISTIDINE (UNII: 4QD397987E)
- SUCROSE (UNII: C151H8M554)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- METHIONINE (UNII: AE28F7PNPL)
- CALCIUM CHLORIDE (UNII: M4I0D6VV5M)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1719246 - Novoeight 1 UNT Injection
- RxCUI: 1719246 - turoctocog alfa 1 UNT Injection [Novoeight]
- RxCUI: 1737559 - turoctocog alfa 1 UNT Injection
- RxCUI: 1737559 - antihemophilic factor, human B-domain truncated recombinant 1 UNT Injection
* Please review the full disclaimer at the bottom of this page.